{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:35:13Z","timestamp":1788564913287,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.jaip.2014.03.007","type":"journal-article","created":{"date-parts":[[2014,5,5]],"date-time":"2014-05-05T23:13:22Z","timestamp":1399331602000},"page":"252-257.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Mast Cell Activation Disorders"],"prefix":"10.1016","volume":"2","author":[{"given":"Cem","family":"Akin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2014.03.007_bib1","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/eji.201040559","article-title":"Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity","volume":"40","author":"Galli","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/978-1-4419-9533-9_1","article-title":"Mast cell biology: introduction and overview","volume":"716","author":"Gilfillan","year":"2011","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jaip.2014.03.007_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.iac.2006.05.005","article-title":"Mast cell mediators in allergic inflammation and mastocytosis","volume":"26","author":"Castells","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2014.03.007_bib4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report: Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2133.1996.tb01495.x","article-title":"Cutaneous manifestations of systemic lupus erythematosus","volume":"135","author":"Yell","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2014.03.007_bib7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-4632.2004.01939.x","article-title":"Cutaneous manifestations associated with antiphospholipid antibodies","volume":"43","author":"Diogenes","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2014.03.007_bib8","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jaci.2012.01.043","article-title":"Chronic urticaria and autoimmunity: associations found in a large population study","volume":"129","author":"Confino-Cohen","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1710-1492-5-10","article-title":"Urticaria and infections","volume":"5","author":"Wedi","year":"2009","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib10","doi-asserted-by":"crossref","first-page":"205.e1","DOI":"10.1016\/j.jaad.2013.07.049","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers","volume":"70","author":"Jawed","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2014.03.007_bib11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-4632.2006.02675.x","article-title":"Cutaneous manifestations of Hodgkin\u2019s disease","volume":"45","author":"Rubenstein","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2014.03.007_bib12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaci.2010.04.009","article-title":"Involvement of mast cells in eosinophilic esophagitis","volume":"126","author":"Abonia","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib14","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2014.03.007_bib15","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"54","article-title":"Mastocytosis","author":"Horny","year":"2008"},{"key":"10.1016\/j.jaip.2014.03.007_bib16","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2014.03.007_bib17","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2014.03.007_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.23672","article-title":"Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis","author":"Kristensen","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2014.03.007_bib19","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0145-2126(03)00093-6","article-title":"Multilineage hematopoietic involvement in systemic mastocytosis","volume":"27","author":"Akin","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2014.03.007_bib20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/leu.2011.293","article-title":"An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis","volume":"26","author":"Teodosio","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2014.03.007_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000048187","article-title":"Cutaneous mastocytosis: clinical heterogeneity","volume":"127","author":"Hartmann","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0145-2126(01)00044-3","article-title":"Clinical and histopathological aspects of cutaneous mastocytosis","volume":"25","author":"Wolff","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2014.03.007_bib23","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","article-title":"Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \u201cidiopathic\u201d anaphylaxis","volume":"110","author":"Akin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2014.03.007_bib24","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib25","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0889-8588(05)70300-2","article-title":"Serum tryptase and the laboratory diagnosis of systemic mastocytosis","volume":"14","author":"Schwartz","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaip.2014.03.007_bib26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000329856","article-title":"Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms","volume":"157","author":"Alvarez-Twose","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib27","first-page":"174","article-title":"Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM)","volume":"3","author":"Valent","year":"2013","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.jaip.2014.03.007_bib28","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1365-2362.2009.02184.x","article-title":"Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology","volume":"39","author":"Sperr","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jaip.2014.03.007_bib29","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2340\/00015555-1486","article-title":"The utility of serum tryptase as a marker in chronic spontaneous urticaria","volume":"93","author":"Siles","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2014.03.007_bib30","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/j.1365-2222.2010.03582.x","article-title":"Serum total tryptase levels are increased in patients with active chronic urticaria","volume":"40","author":"Ferrer","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2014.03.007_bib31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1610-0387.2005.05706.x","article-title":"Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus","volume":"3","author":"Dugas-Breit","year":"2005","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaip.2014.03.007_bib32","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","article-title":"Diagnostic value of tryptase in anaphylaxis and mastocytosis","volume":"26","author":"Schwartz","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2014.03.007_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11588890-000000000-00000","article-title":"Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations","volume":"12","author":"Castells","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2014.03.007_bib34","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0091-6749(97)81058-5","article-title":"Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis","volume":"99","author":"Oude Elberink","year":"1997","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaci.2010.04.025","article-title":"Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase","volume":"126","author":"Rueff","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/cea.12275","article-title":"Predictors of clinical effectiveness of Hymenoptera venom immunotherapy","author":"Rueff","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2014.03.007_bib38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/0310057X1304100120","article-title":"Systemic mastocytosis presenting as intraoperative anaphylaxis with atypical features: a report of two cases","volume":"41","author":"Bridgman","year":"2013","journal-title":"Anaesth Intensive Care"},{"key":"10.1016\/j.jaip.2014.03.007_bib39","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1398-9995.2012.02809.x","article-title":"Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions","volume":"67","author":"van Doormaal","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2014.03.007_bib40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.anai.2013.02.008","article-title":"Mast cell activation syndromes","volume":"111","author":"Lee","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib41","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM198706253162603","article-title":"Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis","volume":"316","author":"Schwartz","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2014.03.007_bib42","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","article-title":"Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production","volume":"147","author":"Butterfield","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2011.04.037","article-title":"Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations","volume":"128","author":"Hamilton","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib44","doi-asserted-by":"crossref","first-page":"e76241","DOI":"10.1371\/journal.pone.0076241","article-title":"Familial occurrence of systemic mast cell activation disease","volume":"8","author":"Molderings","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2014.03.007_bib45","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1517\/14656566.2013.824424","article-title":"Mastocytosis: update on pharmacotherapy and future directions","volume":"14","author":"Cardet","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaip.2014.03.007_bib46","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1081-1206(10)63322-4","article-title":"Idiopathic anaphylaxis: a series of 335 cases","volume":"77","author":"Ditto","year":"1996","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib47","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib48","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.anai.2012.02.021","article-title":"Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab","volume":"108","author":"Bell","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2014.03.007_bib49","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1398-9995.2009.02045.x","article-title":"Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis","volume":"64","author":"Kontou-Fili","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2014.03.007_bib50","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2014.03.007_bib51","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","article-title":"Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells","volume":"39","author":"Krauth","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2014.03.007_bib52","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood-2007-08-104372","article-title":"The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils","volume":"111","author":"Kneidinger","year":"2008","journal-title":"Blood"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219814000981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219814000981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:06:39Z","timestamp":1761973599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219814000981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S2213219814000981"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2014.03.007","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mast Cell Activation Disorders","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2014.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}